12月22日 - ** DimerixDXB.AX股价上涨12.5%至0.63澳元，创七个月来最高水平
** 如果涨势得以保持，该股将创下六个月来的最大盘中涨幅
** 生物技术公司称美国上市生物技术公司 BioMarin Pharmaceutical BMRN.O将以 48 亿美元收购 (link) 公司的美国商业许可合作伙伴 Amicus Therapeutics。
** Amicus Therapeutics 是一家生物制药公司，负责向美国市场授权 DXB 的 DMX-200 药物，用于治疗罕见肾病。
** 包括本交易日在内，该公司股票今年累计上涨 80.89
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.